Keppra Injection, Solution, Concentrate
Product Images NDC 50474-002

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Keppra (NDC 50474-002). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ucb, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Keppra 01)

Chemical structure diagram of levetiracetam, the active ingredient in Keppra injection, solution, concentrate 100 mg/mL by UCB, Inc.*

FDA Label Image

Figure 1 (Keppra 02)

A bar graph comparing the percentage of patients across three treatment groups: Placebo, KEPPRA 1000 mg/day, and KEPPRA 3000 mg/day. The graph shows the percentage of patients on the vertical axis, ranging from 0% to 45%, with the KEPPRA groups having higher percentages than placebo, and statistical significance indicated by asterisks above the KEPPRA bars.*

FDA Label Image

Figure 2 (Keppra 03)

A bar chart comparing the percentage of patients across three groups: Placebo (6.3%, N=111), KEPPRA 1000 mg/day (20.8%, N=106), and KEPPRA 2000 mg/day (35.2%, N=105). The chart visually shows increasing patient percentages with higher KEPPRA dosages.*

FDA Label Image

Figure 3 (Keppra 04)

A bar graph compares the percentage of patients for two groups: Placebo (N=104) at 14.4% and Keppra 3000 mg/day (N=180) at 39.4%. The y-axis is labeled '% of Patients.' An asterisk symbol appears above the Keppra bar indicating statistical significance or special note.*

FDA Label Image

Figure 4 (Keppra 05)

A bar graph comparing the percentage of patients in two groups: Placebo (N=97) and Keppra (N=101). The y-axis represents the percentage of patients, ranging from 0% to 45%. The Placebo group shows 19.6%, while the Keppra group shows 44.6%, with an asterisk indicating statistical significance or a notable difference.*

FDA Label Image

Figure 5 (Keppra 06)

A bar graph comparing the percentage of patients for Placebo (19.6%) and Keppra (43.1%). The x-axis shows treatment groups with sample sizes, and the y-axis is labeled as percentage of patients, ranging from 0% to 45%. An asterisk marks the Keppra bar.*

FDA Label Image

Figure 6 (Keppra 07)

A bar chart comparing the percentage of patients between a placebo group and a KEPPRA (levetiracetam) group. The y-axis indicates percent of patients from 0% to 100%, with the placebo group at 45.2% and the KEPPRA group at 72.2%. The KEPPRA bar includes a statistical significance symbol.*

FDA Label Image

Principal Display Panel (5 mL Vial Carton)

Carton label for Keppra (levetiracetam) injection 500 mg/5 mL (100 mg/mL) concentrate for intravenous use, manufactured by UCB, Inc. The label includes dosing instructions and storage information for 10 single-use 5 mL vials. The product name, strength, NDC 50474-002-63, and barcode are visible, with notes on dilution prior to administration.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.